Depression
Peptides explored for depression — Selank, Semax, Cerebrolysin — with honest framing about why SSRIs and SNRIs remain first-line, where peptide therapy might add value, and the strict caveats around treating mood disorders.
Major depressive disorder affects roughly 8% of US adults annually and is among the leading causes of disability worldwide. The condition is characterized by persistent depressed mood, loss of interest, sleep and appetite disruption, fatigue, cognitive symptoms, feelings of worthlessness, and in severe cases suicidal ideation. The clinical spectrum ranges from mild reactive depression to severe melancholic depression to treatment-resistant depression that fails multiple first-line interventions. Modern treatment is multimodal: SSRIs and SNRIs as first-line pharmacological therapy, evidence-based psychotherapy (cognitive-behavioral therapy, interpersonal therapy), and for treatment-resistant or severe cases, augmentation strategies (atypical antipsychotics, lithium), ketamine/esketamine, ECT, and rTMS.
Peptide therapy for depression is discussed primarily in the context of Russian-developed neuropeptides (Semax, Selank) and Cerebrolysin (a porcine brain-derived peptide preparation). These have been used clinically in Russia and parts of Eastern Europe for decades, with available evidence largely from Russian clinical literature rather than Western RCTs. The honest framing: peptide therapy does not replace evidence-validated antidepressant medication and psychotherapy, particularly in moderate-to-severe depression. Selank may have a modest role for the anxiety and stress-resilience component of depression. Semax has been used in Russia for depression with limited Western validation. Cerebrolysin has more substantial Western trial data but predominantly in stroke and dementia rather than primary depression.
This page covers what's actually known, the strict boundaries between peptide-as-adjunct and peptide-as-replacement, and important caveats for treating mood disorders. It is informational, not medical advice. Severe depression with suicidal ideation requires urgent psychiatric evaluation, not self-directed peptide protocols.
Peptides discussed for Depression
Cerebrolysin
Neurotrophic Peptide Complex
A porcine brain-derived peptide preparation with neurotrophic properties, approved in several countries for stroke recovery and cognitive disorders.
N-Acetyl Selank Amidate
Nootropic Peptide
An enhanced version of Selank with improved stability, studied for anxiety reduction and cognitive enhancement.
Selank
Nootropic Peptide
A synthetic peptide analog of tuftsin with anxiolytic and nootropic properties, developed in Russia.
Semax
Nootropic Peptide
A synthetic peptide analog of ACTH(4-10) developed in Russia, studied for cognitive enhancement and neuroprotection.
NA-Semax-Amidate
Nootropic Peptide
A chemically modified version of Semax designed for improved stability. No published clinical or preclinical data exists for this specific compound.
How peptides target depression
Selank is a synthetic analog of the immunomodulatory peptide tuftsin, modified for enhanced central nervous system activity. It modulates GABAergic neurotransmission and has anxiolytic effects without the sedation, tolerance, or dependence of benzodiazepines. The anxiety component of depression — present in approximately half of major depression cases — is real and often disabling. Selank's mechanism aligns with the same pathways targeted by SSRIs and SNRIs (modulating monoaminergic and GABAergic systems for anxiety and stress resilience), though through different molecular targets.
Semax is a synthetic analog of ACTH(4-10) that enhances BDNF (brain-derived neurotrophic factor) expression and supports neuroplasticity. The 'neuroplasticity hypothesis' of depression — that depressed states reflect impaired synaptic plasticity and reduced BDNF, with antidepressant therapy gradually restoring it over weeks — gives Semax mechanistic alignment with antidepressant biology. Russian clinical use of Semax includes depression among its indications.
Cerebrolysin is a peptide preparation derived from porcine brain tissue, containing low-molecular-weight peptides and amino acids. It has neurotrophic, neuroprotective, and BDNF-modulating effects, with the most substantial trial evidence in stroke recovery and dementia. Its use in depression specifically is less validated, though some Eastern European clinical literature describes use in depressive states.
What peptides do not do for depression: replicate the efficacy of evidence-validated antidepressant therapy in moderate-to-severe depression, address suicidal ideation as an acute intervention, modify the underlying neurobiology in a way that has been validated comparable to SSRIs/SNRIs across thousands of RCT-enrolled patients.
What the evidence shows
There are no Western randomized trials of any peptide as primary antidepressant therapy in major depression. Russian clinical literature describes use of Semax, Selank, and Cerebrolysin in depression among other indications, but the trial design and reporting standards do not meet Western pivotal-trial expectations. A 2024 study examined Semax effects in chronic stress models with antidepressant-like effects in animals; human translation is limited.
For evidence-validated comparators: SSRIs (sertraline, escitalopram, fluoxetine, etc.) and SNRIs (duloxetine, venlafaxine) have hundreds of RCTs supporting them in major depression, with effect sizes in the moderate range (NNT 6-8 for response in moderate-to-severe depression). CBT and IPT have parallel evidence bases. Augmentation strategies (atypical antipsychotics, lithium, T3) for partial responders have substantial RCT evidence. Ketamine and esketamine have rapid-onset efficacy in treatment-resistant depression.
Peptide therapy is positioned as an adjunct or alternative for selected patients, not as primary therapy in moderate-to-severe depression. The reasonable use cases are: Selank for the anxiety component in patients also engaged with primary antidepressant therapy; Semax in mild depression as a complementary intervention; Cerebrolysin in patients with depression complicated by neurological conditions where its broader neurotrophic effects may be relevant.
Important caveats
Severe depression with suicidal ideation requires urgent psychiatric evaluation, not peptide therapy. Patients with active suicidal ideation, plans, or recent attempts need immediate psychiatric crisis evaluation. The 988 Suicide & Crisis Lifeline is available 24/7. Self-directed peptide protocols for severe depression are inappropriate.
Depression management should be coordinated by a psychiatrist, primary care clinician with psychiatric training, or other qualified mental health clinician. SSRIs and SNRIs remain first-line for moderate-to-severe depression with substantial RCT evidence and FDA approval. Evidence-based psychotherapy is foundational regardless of medication strategy. Peptide therapy without engagement with evidence-validated care risks under-treatment of a serious condition.
None of the peptides discussed is FDA-approved for depression. Selank and Semax are Russian-approved only. Cerebrolysin is approved in some jurisdictions outside the US (Russia, parts of Asia) for stroke and dementia, not specifically for depression in most markets. WADA does not currently prohibit these peptides specifically but the S0 'non-approved substances' clause may apply.
Monitoring requirements for depression treatment are significant: regular symptom assessment, suicide risk evaluation, response measurement (PHQ-9 or similar), and adjustment of therapy based on response. Self-directed peptide use without these is inappropriate.
Frequently asked questions
Can peptides replace antidepressants?
No, particularly in moderate-to-severe depression. SSRIs and SNRIs have substantial RCT evidence in major depression with effect sizes that no peptide has matched. Peptides may be reasonable adjuncts for specific components (Selank for anxiety, Semax for cognitive symptoms) but should not replace evidence-validated antidepressant therapy. Patients with severe depression need evidence-based care, not peptide-only protocols.
What is the best peptide for depression?
Selank has the most mechanistically aligned role for the anxiety component of depression. Semax has Russian use base for depression but limited Western validation. Cerebrolysin has the most substantial trial evidence overall, though primarily in stroke and dementia rather than primary depression. None has Western RCT validation for depression as primary therapy. The right framing: peptides are at-most adjuncts to evidence-validated care.
Will Selank help my depression-related anxiety?
Selank has Russian clinical evidence for anxiolytic effects in generalized anxiety disorder, with mechanism modulating GABAergic and serotonergic signaling. The anxiety component of depression is common and often disabling. Selank may help, though without Western RCT validation in depression specifically. SSRI/SNRI medications have stronger evidence and should generally be considered first; Selank may be a complementary intervention under clinical supervision.
Is Cerebrolysin a good peptide for depression?
Cerebrolysin has the most substantial trial evidence overall among peptides discussed for mood disorders, but the strongest evidence is in stroke recovery and dementia rather than primary depression. Some Eastern European literature describes use in depressive states. Its role in primary major depression in evidence-validated frameworks is limited. May be relevant in patients with depression complicated by stroke or neurodegenerative disease where the broader neurotrophic profile is applicable.
When should I see a psychiatrist instead of trying peptides?
Always for moderate-to-severe depression, particularly with: suicidal ideation, plans, or recent attempts (urgent); severe functional impairment; psychotic features; bipolar features (manic episodes); failure to respond to first-line treatment; need for higher-level care. Peptide therapy is not appropriate as primary management in any of these scenarios. The 988 Suicide & Crisis Lifeline is available 24/7 for immediate help.
Part of these goals
Related conditions
Stacks that overlap
- Semax + Selank (The Nootropic Stack)
The Russian nootropic peptide combination — Semax for cognitive enhancement and BDNF upregulation paired with Selank for anxiolytic effects and stress resilience.
Updated 2026-05-08